Cipla Limited is a leading Indian pharmaceutical company engaged in the manufacture, development, and marketing of a broad range of branded and generic formulations and APIs.

The company achieved its highest-ever quarterly revenue in Q2 FY26, reaching INR 7,589 Cr with robust EBITDA margins of 25%, highlighting excellent financial performance.

Cipla's strategic partnership with Eli Lilly to launch Yurpeak in India marks a significant expansion in chronic care, specifically targeting diabetes, which affects millions in India.

Cipla has made significant strides in respiratory care in North America, ranking as the top albuterol MDI supplier with a market share of 22%, reaffirming its leadership in the respiratory space.

Strategic investments and partnerships in biotechnology and generics underline Cipla's focus on expanding its presence in advanced therapeutic segments and maintaining competitive advantage.